Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of “Moderate Buy” by Analysts

Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP) have earned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $48.3333.

A number of equities analysts recently weighed in on the stock. BTIG Research reissued a “buy” rating and set a $47.00 target price on shares of Rapport Therapeutics in a research note on Monday, December 8th. The Goldman Sachs Group reissued a “buy” rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. Wells Fargo & Company set a $51.00 target price on Rapport Therapeutics in a research note on Friday, December 19th. Citizens Jmp lifted their target price on Rapport Therapeutics from $77.00 to $80.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, HC Wainwright boosted their price target on Rapport Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th.

Rapport Therapeutics Price Performance

Shares of RAPP stock opened at $26.81 on Monday. The business’s 50 day simple moving average is $28.40 and its 200 day simple moving average is $23.34. Rapport Therapeutics has a one year low of $6.43 and a one year high of $42.27. The stock has a market capitalization of $1.28 billion, a PE ratio of -9.89 and a beta of 1.63.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.06. As a group, research analysts expect that Rapport Therapeutics will post -3.65 earnings per share for the current year.

Insider Buying and Selling at Rapport Therapeutics

In other news, insider Krishnaswamy Yeleswaram sold 2,840 shares of the firm’s stock in a transaction dated Wednesday, December 31st. The stock was sold at an average price of $30.05, for a total value of $85,342.00. Following the completion of the sale, the insider directly owned 296,991 shares in the company, valued at $8,924,579.55. This trade represents a 0.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider David Bredt sold 8,500 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $26.84, for a total value of $228,140.00. Following the transaction, the insider directly owned 395,575 shares in the company, valued at approximately $10,617,233. This trade represents a 2.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 56,739 shares of company stock valued at $1,578,630. Corporate insiders own 13.57% of the company’s stock.

Institutional Investors Weigh In On Rapport Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. acquired a new position in shares of Rapport Therapeutics during the third quarter worth approximately $43,000. Strs Ohio grew its position in Rapport Therapeutics by 23.5% in the 3rd quarter. Strs Ohio now owns 2,100 shares of the company’s stock valued at $62,000 after purchasing an additional 400 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Rapport Therapeutics by 86.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock valued at $99,000 after purchasing an additional 4,582 shares in the last quarter. Creative Planning bought a new stake in Rapport Therapeutics during the 2nd quarter valued at $121,000. Finally, Kennedy Capital Management LLC acquired a new position in Rapport Therapeutics during the second quarter worth $128,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.